Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 21fludarabine phosphate 18Whole-Body Irradiation 17Methotrexate 17Tacrolimus 15Peripheral Blood Stem Cell Transplantation 15Mycophenolic Acid 13Dexamethasone 11Vincristine 10Etoposide 10Antilymphocyte Serum 10Calcium Dobesilate 9Busulfan 9Rituximab 8Doxorubicin 8merphos 7Filgrastim 7Cytarabine 7Sirolimus 6Prednisone 6Melphalan 6Granulocyte Colony-Stimulating Factor 6Cyclosporine 6pegaspargase 5dexamethasone acetate 5dexamethasone 21-phosphate 5prednylidene 4deltacortene 4auricularum 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × crenigacestat × Clear all
NCT02518113 2019-09-11

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Eli Lilly and Company

Phase 1/2 Completed
36 enrolled 17 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡